Scholarlink

<p>In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016–2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A&#xa0;minimum follow-up of 6&#xa0;months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19% in patients with T3b disease on both MRI and PSMA PET, versus 58% with T3b only on MRI (<i>p</i> = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostische waarde van PSMA PET/CT in het voorspellen van de biochemisch recidiefvrije overleving na radicale prostatectomie in miN0-patiënten

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Vera Sweere,
  • Alexandra Bruins Slot,
  • Rick Hermsen,
  • Joris G. Heetman,
  • Lieke Wever,
  • Jules Lavalaye,
  • Maarten Vinken,
  • Clinton D. Bahler,
  • Mark Tann,
  • Claudia Kesch,
  • Tugce Telli,
  • Wolfgang P. Fendler,
  • Peter Ka-Fung Chiu,
  • Fabio Zattoni,
  • Laura Evangelista,
  • Francesco Ceci,
  • Marcin Miszczyk,
  • Pawel Rajwa,
  • Francesco Barletta,
  • Alberto Briganti,
  • Francesco Montorsi,
  • Giorgio Gandaglia,
  • Jean-Paul A. Van Basten,
  • Harm H. E. Van Melick,
  • Roderick C. N. Van den Bergh,
  • Giancarlo Marra,
  • Matthijs J. Scheltema,
  • Timo F. W. Soeterik

摘要

In this international multicenter retrospective study, we analyzed 476 patients with localized or locally advanced prostate cancer without suspicious lymph node involvement (miN0). All patients were staged with PSMA PET/CT and MRI before radical prostatectomy (2016–2023). We assessed the added value of PSMA PET/CT local staging alongside MRI in predicting biochemical recurrence free survival (BRFS). A minimum follow-up of 6 months was required. Multivariable Cox-regression showed PSA, biopsy ISUP GG, MRI T‑stage and PSMA PET T‑stage as independent predictors of BRFS. The 2‑year BRFS was 19% in patients with T3b disease on both MRI and PSMA PET, versus 58% with T3b only on MRI (p = 0.03). The study supports that PSMA PET/CT-based local staging adds prognostic value beyond MRI alone.